JP4542705B2 - オーストラリア・ブラウン・スネーク，プソイドナジャ・テキスティリス・テキスティリスからのプラスミンインヒビター - Google Patents

オーストラリア・ブラウン・スネーク，プソイドナジャ・テキスティリス・テキスティリスからのプラスミンインヒビター Download PDF

Info

Publication number
JP4542705B2
JP4542705B2 JP2000548371A JP2000548371A JP4542705B2 JP 4542705 B2 JP4542705 B2 JP 4542705B2 JP 2000548371 A JP2000548371 A JP 2000548371A JP 2000548371 A JP2000548371 A JP 2000548371A JP 4542705 B2 JP4542705 B2 JP 4542705B2
Authority
JP
Japan
Prior art keywords
preparation
plasmin
seq
txln
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000548371A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002514404A (ja
JP2002514404A5 (enExample
Inventor
マスシ、パンタレオネ、ポール
ラビン、マーチン、フランシス
ガッフニイ、パトリック、ジョセフ
Original Assignee
ザ ユニバーシィティ オブ クイーンズランド
ナショナル インスチチュート オブ バイオロジカル スタンダーズ アンド コントロール、ユナイテッド キングダム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ユニバーシィティ オブ クイーンズランド, ナショナル インスチチュート オブ バイオロジカル スタンダーズ アンド コントロール、ユナイテッド キングダム filed Critical ザ ユニバーシィティ オブ クイーンズランド
Publication of JP2002514404A publication Critical patent/JP2002514404A/ja
Publication of JP2002514404A5 publication Critical patent/JP2002514404A5/ja
Application granted granted Critical
Publication of JP4542705B2 publication Critical patent/JP4542705B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2000548371A 1998-05-11 1999-05-07 オーストラリア・ブラウン・スネーク，プソイドナジャ・テキスティリス・テキスティリスからのプラスミンインヒビター Expired - Fee Related JP4542705B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPP3450A AUPP345098A0 (en) 1998-05-11 1998-05-11 Novel anti-fibrinolytic agents
AU3450 1998-05-11
PCT/AU1999/000343 WO1999058569A1 (en) 1998-05-11 1999-05-07 PLASMIN INHIBITORS FROM THE AUSTRALIAN BROWN SNAKE $i(PSEUDONAJA TEXTILIS TEXTILIS)

Publications (3)

Publication Number Publication Date
JP2002514404A JP2002514404A (ja) 2002-05-21
JP2002514404A5 JP2002514404A5 (enExample) 2006-07-13
JP4542705B2 true JP4542705B2 (ja) 2010-09-15

Family

ID=3807704

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000548371A Expired - Fee Related JP4542705B2 (ja) 1998-05-11 1999-05-07 オーストラリア・ブラウン・スネーク，プソイドナジャ・テキスティリス・テキスティリスからのプラスミンインヒビター

Country Status (11)

Country Link
US (1) US7070969B1 (enExample)
EP (1) EP1078003B1 (enExample)
JP (1) JP4542705B2 (enExample)
AT (1) ATE440108T1 (enExample)
AU (1) AUPP345098A0 (enExample)
CA (1) CA2328431C (enExample)
DE (1) DE69941292D1 (enExample)
DK (1) DK1078003T3 (enExample)
ES (1) ES2332249T3 (enExample)
NZ (1) NZ508770A (enExample)
WO (1) WO1999058569A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP345098A0 (en) * 1998-05-11 1998-06-04 National Institute Of Biological Standards And Control, United Kingdom Novel anti-fibrinolytic agents
US6506365B1 (en) * 2000-09-25 2003-01-14 Baxter Aktiengesellschaft Fibrin/fibrinogen binding conjugate
US7745192B2 (en) * 2002-04-03 2010-06-29 Venomics Pty Limited Prothrombin activating protein
PT1976985E (pt) 2005-12-29 2013-10-24 Univ California Métodos e composições relacionados com o domínio 1 mutante de kunitz do tfpi-2
EP2154152A1 (en) * 2008-08-08 2010-02-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Use of Conkunitzin-S1 for the modulation of glucose-induced insulin secretion
EP2359852A4 (en) * 2008-11-17 2015-05-20 Nat Cancer Ct NEW CANCERED THERAPY WITH A SUBSTANCE COMPLEX SPECIFICALLY BINDING TO A TUMOR STREAM FACTOR AND ANTITUMIR COMPOUND
CN102850451B (zh) * 2011-06-29 2014-05-07 辽宁诺康生物制药有限责任公司 具有抑制纤溶酶活性的重组textilinin-1及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342830A (en) * 1990-11-16 1994-08-30 Cor Therapeutics, Inc. Antithrombosis agents
EP0585504A1 (en) * 1992-09-04 1994-03-09 Pentapharm A.G. Phospholipid dependant prothrombin activator and its use in lupus anticoagulant testing
AUPP076797A0 (en) * 1997-12-05 1998-01-08 Active (Pla) R&D Pty Ltd Phospholipase inhibitor
AUPP345098A0 (en) * 1998-05-11 1998-06-04 National Institute Of Biological Standards And Control, United Kingdom Novel anti-fibrinolytic agents

Also Published As

Publication number Publication date
EP1078003B1 (en) 2009-08-19
EP1078003A1 (en) 2001-02-28
JP2002514404A (ja) 2002-05-21
EP1078003A4 (en) 2004-08-25
DE69941292D1 (de) 2009-10-01
AUPP345098A0 (en) 1998-06-04
CA2328431A1 (en) 1999-11-18
US7070969B1 (en) 2006-07-04
NZ508770A (en) 2003-12-19
ATE440108T1 (de) 2009-09-15
DK1078003T3 (da) 2009-12-07
WO1999058569A1 (en) 1999-11-18
CA2328431C (en) 2010-04-27
ES2332249T3 (es) 2010-01-29

Similar Documents

Publication Publication Date Title
US6087487A (en) Nematode-extracted serine protease inhibitors and anticoagulant proteins
JP3122127B2 (ja) 抗凝血タンパク質
KR0138997B1 (ko) 흡혈박쥐 타액 플라스미노겐 활성인자
US5639726A (en) Peptide mediated enhancement of thrombolysis methods and compositions
JP3189052B2 (ja) 抗血液凝固活性を有するポリペプチド
JPH02121934A (ja) 組合せ医薬組成物
CZ20031718A3 (cs) Polypeptidická proteáza štěpící von Willebrandův faktor (vWF), nukleová kyselina kódující tento polypeptid a použití tohoto polypeptidu
JPWO1992000325A1 (ja) 抗血液凝固活性を有するポリペプチド
US5239058A (en) Proteins having anticoagulant properties
US5945275A (en) Nematode-extracted anticoagulant protein
EP0652900B1 (en) Thrombin inhibitors
JP2002514404A (ja) オーストラリア・ブラウン・スネーク，プソイドナジャ・テキスティリス・テキスティリスからのプラスミンインヒビター
JPH10505502A (ja) 修飾されたコラーゲン誘導血小板凝集阻害剤パリジピンの製法
HU220301B (hu) Véralvadásgátló protosztómiák (vérszívók) nyálából
US7615527B2 (en) Peptides which modulate blood coagulation and methods of use thereof
EP0713496A1 (en) Fibrin-targeted inhibitors of thrombin
US5328997A (en) Processes for making proteins having anticoagulant properties
AU759190B2 (en) Plasmin inhibitors from the Australian brown snake (Pseudonaja textilis textilis)
US5801017A (en) Production of recombinant factor Xa inhibitor of leech Hirudo medicinalis
TW200846356A (en) Preparation and use of variants of the kunitz domain 2 of the human placental bikunin gene
JPH08333400A (ja) 抗血栓活性を有する融合蛋白質及びその製法
WO1999060126A9 (en) Protein z-dependent protease inhibitor
JP2899561B2 (ja) トロンビンによるプロテインｃの活性化を促進するペプチドのシグナル配列
JPH05252954A (ja) 新規な組織因子インヒビターをコードする遺伝子断片
JPH07242700A (ja) 新規ポリペプチド

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060425

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060425

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090519

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090819

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090924

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091007

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091019

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091119

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100129

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100430

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100512

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100525

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100615

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100628

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130702

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees